PROMINENT Trial: Pemafibrate Lowers Triglycerides Without CV Benefits — Is This the Nail in the Coffin For Fibrates? – American College of Cardiology
Although elevated triglyceride levels are associated with an increased risk of myocardial infarction (MI), ischemic stroke, and all-cause mortality,1 previous trials have failed to demonstrate a significant clinical benefit from the use of triglyceride lowering therapies. However, a prespecified subgroup analysis from the ACCORD trial suggested that fibrates, in combination with statins, may…
